CXCL8 and gastric cancer: The most significant reduction in IL-6 and IL-8 concentrations was observed after the exposition of AGS gastric cancer cells to a combination of trastuzumab and Les-4367, compared with monotherapy and a combination of pertuzumab with Les-4367.